Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation-Reference-Cited by-同舟云学术

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation

Published:2020-05-20 Issue:7 Volume:11 Page:1934-1943
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Lian Zengzhi¹,Du Wenwen¹²,Zhang Yang¹²,Fu Yulong¹,Liu Ting¹²,Wang Anqi¹²,Cai Tingting¹²,Zhu Jianjie¹²³,Zeng Yuanyuan¹²³,Liu Zeyi¹²³^ORCID,Huang Jian‐an¹²³

Affiliation:

1. Department of Respiratory MedicineThe First Affiliated Hospital of Soochow University Suzhou China

2. Institute of Respiratory DiseasesSoochow University Suzhou China

3. Suzhou Key Laboratory for Respiratory Diseases Suzhou China

Funder

Beijing Medical and Health Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13485

Reference38 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Lung Cancer

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

5. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory Effect of the Multi-target TKI, Anlotinib, in 5-FU Resistant Colorectal Cancer HCT-8/15 Cells: Down Regulation of Drug Resistance-associated Protein Expression.;2024-06-05

2. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study;Cancer Immunology, Immunotherapy;2024-05-17

3. Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF;Toxicology and Applied Pharmacology;2024-05

4. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study;International Journal of General Medicine;2023-09

5. Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming;Advanced Therapeutics;2023-07-21